We give you a written timeline estimate for your case before you commit.Ask about treatment
Colorectal cancer (colon and rectal cancer): US-approved treatments and how families in the Gulf can access them
A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Colorectal cancer: the short answer
The US FDA has approved five medicines covered on this page for colorectal cancer, each for a specific group of patients: Braftovi, Krazati, Fruzaqla, Keytruda and Opdivo. On 17 October 2026, five of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Braftovi, Krazati, Fruzaqla, Keytruda and Opdivo.
- Gulf registers (checked 17 October 2026): see each medicine below.
- Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is colorectal cancer?
Colon cancer is a type of cancer that forms in the tissues of the colon, the main part of the large intestine. The rectum and anal canal make up the last part of the large intestine. Health history affects the risk of developing colon cancer.[1]
Signs of colon cancer include blood in the stool or a change in bowel habits. Tests that examine the colon and rectum are used to diagnose it, and imaging tests check whether it has spread.[1]
Surgery is the most common treatment for all stages of colon cancer. For cancer that has spread, treatment choices depend on tumor tests such as BRAF V600E, KRAS G12C and microsatellite instability (MSI-H or dMMR).[1, 2, 3, 4]
Colorectal cancer in the Gulf
Gulf research on colorectal cancer includes a review of its molecular pathology in Saudi Arabia (2023) and a systematic review of dietary and lifestyle factors in colorectal cancer prevention in the Gulf Cooperation Council countries (2024).[5, 6]
We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 3 of 5 were listed in Saudi Arabia and 5 of 5 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[7, 8]
US FDA-approved medicines for colorectal cancer
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Braftovi (encorafenib)
US FDA-approved for adults with metastatic colorectal cancer with a BRAF V600E mutation, in combination with cetuximab and fluorouracil-based chemotherapy. It is a capsule.[2]
Current US label version: 26 February 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[7, 8]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Krazati (adagrasib)
US FDA-approved for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, in combination with cetuximab (accelerated approval). It is a tablet.[3]
Current US label version: 25 March 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[7, 8]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Fruzaqla (fruquintinib)
US FDA-approved for adults with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, an anti-VEGF therapy and, if suitable, an anti-EGFR therapy. It is a capsule.[9]
Current US label version: 31 July 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[7, 8]
Country access guides: UAE, Qatar, Oman, Egypt, India - Keytruda (pembrolizumab)
US FDA-approved for adults with unresectable or metastatic MSI-H or dMMR colorectal cancer. It is an immunotherapy infusion.[4]
Current US label version: 10 July 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[7, 8]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Opdivo (nivolumab)
US FDA-approved for adults and children 12 and older with unresectable or metastatic MSI-H or dMMR colorectal cancer, including with ipilimumab. It is an immunotherapy infusion.[10]
Current US label version: 12 August 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[7, 8]
How families in the Gulf can access treatment
If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[11, 12] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
- Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for colorectal cancer
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for colorectal cancer?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Braftovi, Krazati, Fruzaqla, Keytruda and Opdivo. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Braftovi available in Saudi Arabia or the UAE?
We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.
How can a family in the Gulf get Braftovi?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Does Reserve Meds diagnose or prescribe?
No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.
Why are tumor gene tests important in colorectal cancer?
Several US labels apply only to tumors with a specific finding: Braftovi to BRAF V600E, Krazati to KRAS G12C, and Keytruda and Opdivo to MSI-H or dMMR colorectal cancer.
Sources for the condition-specific answers: [2, 3, 4, 10]
Sources
Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.
- National Cancer Institute (NCI): Colon Cancer Treatment
- DailyMed: BRAFTOVI (encorafenib) US prescribing information, label version 26 February 2026
- DailyMed: KRAZATI (adagrasib) US prescribing information, label version 25 March 2026
- DailyMed: KEYTRUDA (pembrolizumab) US prescribing information, label version 10 July 2026
- Alfahed A, et al. Molecular pathology of colorectal cancer: The Saudi situation in perspective. Saudi Med J. 2023 (PubMed 37717975)
- Rashed Adam T, et al. A Systematic Review of the Impact of Dietary and Lifestyle Factors on Colorectal Cancer Prevention in Gulf Cooperation Council Countries. Cureus. 2024 (PubMed 39411590)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed: FRUZAQLA (fruquintinib) US prescribing information, label version 31 July 2026
- DailyMed: OPDIVO (nivolumab) US prescribing information, label version 12 August 2026
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Gastric (stomach) cancer
- Liver cancer (hepatocellular carcinoma)
- Crohn's disease
- Braftovi: drug overview
- Krazati: drug overview
- Fruzaqla: drug overview
- Named-patient access in the Gulf, explained
- US-approved medicines not yet registered in the Gulf
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
- यह पृष्ठ हिंदी में पढ़ें
- یہ صفحہ اردو میں پڑھیں
This page is general health information, not medical advice. It does not replace a consultation with your doctor.